Related Experiment Video
Updated: Dec 2, 2025

Cardiopulmonary Bypass in a Mouse Model: A Novel Approach
Published on: September 22, 2017
Impact of miniaturized cardiopulmonary bypass circuits on ultrafiltration during congenital heart surgery
Keye Wu1, Baoying Meng1, Yuanxiang Wang1
1Department of Cardiothoracic Surgery, Shenzhen Children's Hospital, Shenzhen, China.
Objective:
To investigate whether the miniaturized cardiopulmonary bypass (CPB) system decreased the usage of ultrafiltration (UF), and to explore whether the non-UF with miniaturized CPB strategy could get good clinical results during congenital heart surgery.
Methods:
We performed a retrospective analysis of all patients undergoing congenital heart surgery with CPB at Shenzhen Children's Hospital from 1 May 2015 to 30 September 2019. We classified patients to UF with miniaturized CPB group, non-UF with miniaturized CPB group, UF with conventional CPB group and non-UF with conventional CPB group.
Results:
Of the 2145 patients, 721 (33.6%) were in the conventional CPB group, and 1424 (66.4%) were in the miniaturized CPB group. The UF rate was significantly lower in the miniaturized CPB group compared with that in the conventional CPB group (12.5% vs. 76.8%, p < 0.001). Compared with patients in the other groups, patients in the non-UF with miniaturized CPB group had a shorter postoperative MV time (p < 0.05), and a shorter length of stay in the ICU (p < 0.001) and hospital (p < 0.001). The age of children in the UF with miniaturized CPB group was relatively younger (median: 1.5 months, IQR: 0.3-4.6 months), and the preoperative weight was relatively lower (median: 3.9 kg, IQR: 3.2-5.4 kg). Moreover, this group of children had a relatively longer postoperative MV time and length of stay in the ICU and hospital.
Conclusion:
The miniaturized CPB system could decrease the usage of UF. Good results were achieved in children who did not use UF based on the miniaturized CPB circuit system during congenital heart surgery.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Heart Failure VI: Adjunct Therapies

